Suloexide in the Treatment of Early Stages of COVID-19
Status:
Completed
Trial end date:
2020-09-07
Target enrollment:
Participant gender:
Summary
Problem:
The COVID- 19 pandemic has not only affected our healthcare system, but the impact on the
worldwide financial systems and our "normal" way of life is still to be determined.
Although the percentage of patients infected with COVID-19 that need hospital care is low,
Its high rate of contagiousness makes the total number of patients in need of hospital care
cripple any healthcare system, limiting the space available for other patients in need of
critical care, who cannot be admitted or even prefer not to attend the hospital in fear of
infection.
Early investigations report an Increase risk of thromboembolic complications, and a systemic
inflammatory response not clearly understood. There is a possible vascular endothelial
dysfunction due to chronic comorbidities (Hypertension, diabetes, obesity, chronic kidney
disease, lung disease) as a risk factor for a more severe presentation.
Justification:
Sulodexide is a two-compound drug, each of them with different endothelial action that can be
beneficial in COVID-19 patients.
Glycosaminoglycans: Can help restore venous and arterial endothelial glycocalyx which can
downregulate or limit the response to inflammatory molecules, by maintaining the integrity
lost in certain chronic diseases (high blood pressure, diabetes).
Heparin compound: It has an antithrombotic effect that could help reduce the incidence of
thromboembolic complications, and also add to the anti-inflammatory response due to it
anti-thrombin action (similar or a bit less to that of low molecular weight heparin) with
less risk of major bleeding.
It's a medication that can be used orally with minimal adverse effects and is less expensive
than low molecular weight heparin.
Hypothesis:
We hypothesize that sulodexide instituted early in populations at significant risk and
symptomatic patients affected with COVID-19 (shortness of breath, fever, weakness, diarrhoea)
and risk factors of diabetes, hypertension, COPD, atherosclerosis, chronic kidney disease,
will provide improvement in endothelial integrity, decrease inflammatory responses, and
improved clinical outcomes with decreased hospital admission, decrease VTE and arterial
complications, morbidity, and mortality.
Objective:
To use sulodexide in patients that have early onset of COVID-19 symptoms to mitigate the
progression of the disease process that can allow them to recover at home, and limit the need
of hospital care and a more severe clinical manifestation